Andere Sprachen Galectin Therapeutics Inc.

Aktien

A1JV3R

US3632252025

GALT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
3.45 ^USD	-1.43%		+2.37%	+107.83%

29.03.	Galectin Therapeutics Inc. ernennt Benjamin S. Carson zum Mitglied des Board of Directors	CI
29.03.	Galectin Therapeutics Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Galectin Therapeutics : Corporate Presentation, April 2024	17.04.
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension	10.04.
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis	09.04.
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	01.04.
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	29.03.
Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	29.03.
Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K	29.03.
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
North American Morning Briefing : Stocks Set for -2-	28.03.
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development	12.03.
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update	13.11.
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
North American Morning Briefing : Stock Futures -2-	13.11.
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD	03.11.
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023	23.10.23
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors	12.10.23
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension	04.10.23
Galectin Says Data and Safety Monitoring Board Approves Continuation of Belapectin Study Without Modifications.	03.10.23
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis	03.10.23
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE	03.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Galectin Therapeutics Inc.

Aktien

A1JV3R

US3632252025

GALT

Andere Sprachen

Filter